Brain Metastases - SRS Versus Whole Brain Selection

Key Points

• SRS is recommended for many patients with 1 to 4 brain metastases and reasonable performance status.
• SRS can also be appropriate for selected patients with 5 to 10 metastases; total volume and lesion characteristics matter.
• Large symptomatic lesions with mass effect may require surgery before or instead of SRS.
• Routine WBRT added to SRS for limited disease is avoided because of neurocognitive toxicity.
• Hippocampal avoidance and memantine reduce cognitive toxicity when WBRT is appropriate and eligibility criteria are met.
• Postoperative cavity SRS is commonly preferred over WBRT after resection of limited metastases.
• Symptomatic brain metastases generally require upfront local therapy even when CNS-active systemic therapy exists.
• Asymptomatic patients with effective CNS-active systemic options may occasionally defer radiation after multidisciplinary discussion.
• Close MRI surveillance is mandatory after focal therapy because new brain metastases can develop.
• Poor-prognosis patients may benefit more from supportive care than from burdensome WBRT.

Algorithm

1. Assess neurologic symptoms, performance status, extracranial disease, prognosis, and current systemic therapy.
2. Obtain contrast-enhanced brain MRI with thin-slice stereotactic-quality imaging when feasible.
3. Identify lesions requiring urgent surgery because of size, mass effect, hemorrhage, or diagnostic uncertainty.
4. For 1 to 4 suitable lesions, favor SRS in patients with reasonable performance status.
5. For 5 to 10 lesions, assess total volume, lesion size/location, prognosis, and feasibility of SRS.
6. For diffuse or very extensive disease unsuitable for focal therapy, consider WBRT or supportive care based on prognosis.
7. When WBRT is chosen and eligible, use hippocampal avoidance plus memantine.
8. After resection of limited disease, plan cavity SRS unless another strategy is more appropriate.
9. Coordinate radiation timing with CNS-active systemic therapy and monitor with serial MRI.

Clinical Synopsis & Reasoning

Brain-metastasis radiation decisions should begin with urgency. Symptomatic lesions causing mass effect, edema, hydrocephalus, hemorrhage, seizures, or focal neurologic deficits require prompt local management and often corticosteroids for edema. Large lesions with significant mass effect may be better served by surgical resection followed by focal radiation to the cavity rather than radiosurgery alone. Pathology from surgery can also clarify diagnosis when the intracranial lesion is the first presentation of cancer or when treatment resistance creates diagnostic uncertainty.

For intact metastases, the 2022 ASTRO guideline recommends SRS for patients with one to four brain metastases and reasonable performance status and conditionally recommends SRS for five to ten lesions in appropriately selected patients. Lesion number is not the only variable. Total intracranial tumor volume, largest lesion diameter, proximity to critical structures, expected survival, extracranial disease control, and ability to undergo MRI surveillance are all important. Hypofractionated SRS can reduce radionecrosis risk when lesions are too large for a safe single-fraction dose but remain suitable for focal therapy.

Whole-brain radiation treats visible and microscopic disease throughout the brain but exposes normal brain tissue. Because WBRT is associated with neurocognitive decline, routine addition of WBRT to SRS for limited metastases is generally avoided. When WBRT is the preferred strategy in a patient with favorable prognosis, hippocampal avoidance and memantine should be used when anatomically and clinically appropriate to reduce neurocognitive toxicity. Patients with very poor prognosis may not gain survival or quality-of-life benefit from WBRT; supportive care or a short palliative course can be more appropriate.

After surgical resection of limited brain metastases, postoperative SRS to the cavity is commonly preferred over WBRT because it improves local control while preserving cognition better than whole-brain treatment. Preoperative SRS is an emerging and conditionally supported option in selected centers. The decision must account for cavity size, surgical timing, leptomeningeal-risk considerations, and logistics.

CNS-active targeted therapies and immunotherapies have complicated sequencing. In asymptomatic patients with a targetable mutation and effective CNS-active systemic therapy, local therapy may sometimes be deferred after multidisciplinary discussion and close MRI surveillance. Symptomatic brain metastases still generally require upfront local therapy. The radiation plan should therefore be coordinated with medical oncology and neurosurgery rather than chosen from lesion count alone.

Treatment Strategy & Disposition

SRS is delivered with a highly conformal dose to each lesion or resection cavity using image guidance and rigid quality assurance. Dose and fractionation depend on lesion size, location, prior radiation, and normal-tissue constraints. Small lesions can often receive single-fraction SRS; larger lesions may be treated over three to five fractions. Steroids are not routinely needed for every asymptomatic SRS patient but are appropriate when symptomatic edema is present. Antiseizure therapy is used for patients with seizures and is not routinely given prophylactically to every patient with a brain metastasis.

WBRT is generally used when disease burden is diffuse, numerous lesions cannot reasonably be treated focally, leptomeningeal spread requires broader fields in selected cases, or a patient's disease pattern makes repeated SRS impractical. Hippocampal-avoidance WBRT requires absence of metastases near the hippocampal avoidance region and suitable planning anatomy. Memantine is typically started with WBRT and continued for a defined course when not contraindicated.

Follow-up MRI is essential after SRS because focal treatment does not prevent new metastases elsewhere in the brain. Imaging often occurs every two to three months initially, individualized to disease biology and systemic therapy. Enlarging treated lesions can represent tumor progression, radiation necrosis, or mixed pathology; advanced MRI, PET, serial imaging, corticosteroid response, bevacizumab, surgery, or biopsy may be needed. Repeat SRS can treat selected new or recurrent lesions, but cumulative dose and normal-brain exposure must be reviewed.

Urgent deterioration requires evaluation for edema, hemorrhage, obstructive hydrocephalus, seizures, and mass effect. Dexamethasone is commonly used for symptomatic vasogenic edema, followed by the shortest effective taper. Neurosurgical decompression can be lifesaving for large accessible lesions with mass effect. Goals of care should be integrated because intracranial treatment burden must remain proportional to expected benefit.

Epidemiology / Risk Factors

• Brain metastases are more common than primary malignant brain tumors in adults.
• Lung cancer, breast cancer, melanoma, renal cell carcinoma, and several other solid tumors frequently metastasize to brain.
• Improved systemic therapy and MRI surveillance have increased the number of patients living long enough to develop intracranial metastases.
• Many patients now present with multiple small lesions that remain amenable to SRS.
• Molecular subtype strongly affects intracranial behavior and responsiveness to CNS-active systemic therapy.

Investigations

Typical Selection Clues

Pharmacology

Prognosis / Complications

• Prognosis depends on tumor type, molecular subtype, performance status, extracranial disease, intracranial burden, and treatment response.
• SRS provides high local-control rates for appropriately selected small metastases.
• New distant brain metastases remain common after SRS, so surveillance and salvage treatment are part of the strategy.
• Postoperative SRS preserves cognition better than adjuvant WBRT while maintaining good cavity control in selected patients.
• Patients with poor performance status and uncontrolled systemic disease may have limited benefit from aggressive intracranial radiation.

Patient Education / Counseling

• Explain that SRS is focused radiation and does not treat microscopic disease throughout the brain.
• Discuss the need for repeated MRI surveillance and the possibility of future SRS for new lesions.
• Explain why WBRT may be recommended when disease is too extensive for focal treatment and how memantine and hippocampal avoidance can reduce cognitive effects.
• Review steroid adverse effects if dexamethasone is needed for edema.
• Tell patients to seek urgent care for new weakness, severe headache, seizure, confusion, repeated vomiting, or sudden speech or vision change.
• Discuss treatment goals and expected quality-of-life impact in the context of overall cancer prognosis.

Notes

The 2022 ASTRO brain-metastases guideline emphasizes that SRS selection should incorporate total tumor volume, lesion location, age, extracranial disease, and prognosis rather than relying exclusively on lesion number. This has supported broader use of SRS in carefully selected patients with more than four metastases.

Neurocognitive preservation has become a major treatment endpoint. Avoiding routine WBRT for limited disease, using postoperative SRS, applying hippocampal avoidance when feasible, and prescribing memantine when WBRT is needed all reflect that priority.

Radiation necrosis risk increases with treated volume, dose, prior radiation, and some systemic therapies. Imaging changes after SRS should therefore be reviewed by a multidisciplinary team before declaring treatment failure and switching systemic therapy.

References

1. ASTRO Clinical Practice Guideline on Radiation Therapy for Brain Metastases — Link
2. ASCO-SNO-ASTRO Guideline on Treatment for Brain Metastases — Link